Celgene beats by $0.09, beats on revs; guides FY18 in-line; reaffirms 2020 outlook; Submission of NDA and MAA for ozanimod in relapsing multiple sclerosis expected in 1Q19
- Reports Q1 (Mar) earnings of $2.05 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus of $1.96; revenues rose 19.4% year/year to $3.54 bln vs the $3.47 bln Capital IQ Consensus.
- Revlimid sales +19% to 2.2 bln; Pomalyst/Imnovid +24% to $453 mln; Otezla +46% to $353 mln
- Co issues in-line guidance for FY18, sees EPS of $8.45 from $8.70-8.90 including Juno, excluding non-recurring items, vs. $8.45 Capital IQ Consensus Estimate; sees FY18 revs of $14.8 bln from $14.4-14.8 bln) vs. $14.81 bln Capital IQ Consensus Estimate.
- Submission of NDA and MAA for ozanimod in relapsing multiple sclerosis expected in Q1:19
- "Strong global demand and excellent commercial execution drove our exceptional first quarter results, leading to improvement in our 2018 financial guidance," said Mark J. Alles, Chairman and Chief Executive Officer of Celgene Corporation. "With multiple catalysts for growth expected over the next 12 to 18 months, we are reaffirming our 2020 outlook."